Biogen Idec Stock Hits New 52-Week High (BIIB)
NEW YORK (
) --
(Nasdaq:
) hit a new 52-week high Wednesday as it is currently trading at $120.78, above its previous 52-week high of $120.66 with 962,117 shares traded as of 11:30 a.m. ET. Average volume has been 1.6 million shares over the past 30 days.
Biogen Idec has a market cap of $28.43 billion and is part of the
sector and
industry. Shares are up 7.2% year to date as of the close of trading on Tuesday.
Biogen Idec Inc. discovers, develops, manufactures, and markets therapeutics in the areas of neurology, immunology, hemophilia, and oncology in the United States and internationally. The company has a P/E ratio of 24.3, below the average drugs industry P/E ratio of 24.4 and above the S&P 500 P/E ratio of 17.7.
- Sign up for TheStreet's FREE Dividend and Income Investor Newsletter
TheStreet Ratings rates Biogen Idec as a
. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and increase in net income. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. You can view the full
.
See all
52-week high stocks
or get investment ideas from our
.
null
